Chemclin Diagnostics Co., Ltd. (SHA:688468)

Market Cap	2.61B -13.4%
Revenue (ttm)	322.53M -14.1%
Net Income	35.11M -53.0%
EPS	0.09 -52.1%
Shares Out	394.59M
PE Ratio	74.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,245,981
Open	6.78
Previous Close	6.69
Day's Range	6.61 - 6.98
52-Week Range	5.50 - 8.55
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Chemclin Diagnostics

Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sale of clinical immuno chemiluminescence diagnostic reagents and instruments in China. The company offers the LiCA series of diagnostic reagents, which is based on photo-induced chemiluminescence; the Chemclin series of diagnostic reagents and instruments, which is based on enzyme-catalyzed chemiluminescence; and routine clinical chemistry diagnostic reagents. Its products are used for the detection of biomarkers for infectious diseases, such as hepatitis B, h...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2005
• Employees: 573
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688468

Financial Performance

In 2025, Chemclin Diagnostics's revenue was 332.68 million, a decrease of -23.75% compared to the previous year's 436.29 million. Earnings were 43.91 million, a decrease of -65.44%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 8, 2026

Data Sources Report a data error